Celldex Therapeutics, Inc. financial data

Symbol
CLDX on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
53 Frontage Road, Suite 220, Hampton, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
AVANT IMMUNOTHERAPEUTICS INC (to 9/29/2008), T CELL SCIENCES INC (to 8/21/1998)
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.44K % +68.7%
Debt-to-equity 4.74 % -47.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 66.3M shares +40.4%
Common Stock, Shares, Outstanding 66.3M shares +40.4%
Entity Public Float 1.6B USD +23.1%
Common Stock, Value, Issued 66K USD +40.4%
Weighted Average Number of Shares Outstanding, Basic 66.3K shares +40.3%
Weighted Average Number of Shares Outstanding, Diluted 66.3K shares +40.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 9.98M USD +129%
Research and Development Expense 147M USD +33.1%
General and Administrative Expense 37.1M USD +29.4%
Costs and Expenses 197M USD +41.3%
Operating Income (Loss) -187M USD -38.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -112M USD -58.8%
Earnings Per Share, Basic -2.58 USD/shares +2.64%
Earnings Per Share, Diluted -2.58 USD/shares +2.64%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 36.4M USD +72.2%
Marketable Securities, Current 720M USD +236%
Assets, Current 779M USD +217%
Property, Plant and Equipment, Net 4.23M USD +1.63%
Operating Lease, Right-of-Use Asset 3.17M USD +10.7%
Intangible Assets, Net (Excluding Goodwill) 27.2M USD 0%
Other Assets, Noncurrent 9.75M USD +9009%
Assets 823M USD +194%
Accounts Payable, Current 1.11M USD -68.9%
Employee-related Liabilities, Current 9.35M USD +24.2%
Accrued Liabilities, Current 28.2M USD +52.7%
Liabilities, Current 32.1M USD +15.3%
Operating Lease, Liability, Noncurrent 1.71M USD +31.5%
Other Liabilities, Noncurrent 3.47M USD -21.1%
Liabilities 37.3M USD +11.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 5.29M USD +148%
Retained Earnings (Accumulated Deficit) -1.51B USD -11.4%
Stockholders' Equity Attributable to Parent 786M USD +219%
Liabilities and Equity 823M USD +194%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -40.6M USD -42.2%
Net Cash Provided by (Used in) Financing Activities 436M USD +62740%
Net Cash Provided by (Used in) Investing Activities -315M USD -700%
Common Stock, Shares Authorized 297M shares 0%
Common Stock, Shares, Issued 66.3M shares +40.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 80.3M USD +225%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 36.4M USD +72.2%
Deferred Tax Assets, Valuation Allowance 347M USD +11.1%
Deferred Tax Assets, Gross 353M USD +10.9%
Operating Lease, Liability 2.54M USD -37%
Payments to Acquire Property, Plant, and Equipment 344K USD -41.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -151M USD -23.3%
Lessee, Operating Lease, Liability, to be Paid 2.74M USD -39.8%
Property, Plant and Equipment, Gross 26.4M USD +4.23%
Operating Lease, Liability, Current 1.38M USD -10.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 949K USD -49.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.79M USD +0.68%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 195K USD -62.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 896K USD +1127%
Deferred Tax Assets, Operating Loss Carryforwards 198M USD +4.97%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 3M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 775K USD +6.75%
Share-based Payment Arrangement, Expense 31.7M USD +49.5%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%